EPSILOGEN
8.7.2024 08:01:30 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RSA Announces Expanded Partnership with Microsoft, Enhances Leadership in Passwordless Identity Security24.3.2026 17:00:00 CET | Press release
Innovative partnership ushers in new era of secure, AI-powered workforce authentication RSA today announced expanded support for the new Microsoft 365 E7: The Frontier Suite solution at RSAC Conference 2026. This new support joins additional passwordless capabilities that provide organizations with enhanced security, seamless experience, and resilient operations as they embrace the future of AI-driven productivity. By integrating RSA® ID Plus for Microsoft with Microsoft 365 E7, enterprises can ensure trusted authentication for both human users and AI agents, while safeguarding sensitive data and privileged operations across hybrid, cloud, and on-premises environments. This deployment follows RSA joining the Microsoft Intelligent Security Association (MISA), launching RSA Advisor for Admin Threats in Microsoft Security Copilot, and deploying RSA ID Plus Admin Logs Connector, further strengthening the ongoing collaboration between RSA and Microsoft. “The rise of AI agents in the enterpr
Lexon × Jeff Koons Unveil the Chromatic Collection: a Colorful New Chapter for the Acclaimed Balloon Dog Lamp and Balloon Dog Speaker24.3.2026 15:10:00 CET | Press release
Eight new models introduce vibrant color variations, expanding the collection’s appeal to new and existing collectors alike. Following the success of its 2025 inaugural edition, the Lexon × Jeff Koons collaboration enters a bold new era with the launch of the Chromatic Collection—a colorful evolution of its Balloon Dog Lamp and Balloon Dog Speaker. Pre-orders will be available starting March 24, 2026, exclusively on lexon-design.com as part of a time-limited edition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324498068/en/ Lexon x Jeff Koons — new Chromatic Collection Retaining the signature translucent body that reveals the technology within, the Chromatic Collection introduces eight models: Balloon Dog Lamps in Gold, Blue, Red, and Platinum, and Balloon Dog Speakers in Gold, Blue, Red, and White, reinforcing the collectible nature of the series, offering new audiences an entry point while giving existing collectors
iQmetrix Joins TM Forum as ODA Component Directory Partner, Giving Telecom Operators a Faster, Cleaner Path to Modern Commerce24.3.2026 15:00:00 CET | Press release
Platform’s Standards-Based Architecture Reduces Integration Risk and Accelerates Transformation for CSPs Worldwide iQmetrix, the global provider of Interconnected Commerce solutions purpose-built for telecom retail, today announced it has joined TM Forum and earned recognition as an Open Digital Architecture (ODA) Component Directory Partner. The achievement validates that iQmetrix aligns with the ODA vision and that its platform is built around standardized open APIs, modular cloud-native components, and interoperable architecture aligned with how leading operators are building their digital futures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324562860/en/ iQmetrix partners with TM Forum’s ODA Component Directory to accelerate open, future‑ready telecom transformation The recognition comes as communications service providers (CSPs) accelerate AI adoption and move away from integration-heavy legacy environments. For o
Miro Acquires Reforge to Help Organizations Navigate the Transition to AI24.3.2026 14:00:00 CET | Press release
Together, Reforge and Miro will provide a powerful and highly differentiated solution for teams that blends the tools and knowledge needed to innovate in the AI era Miro®, the AI Innovation Workspace for teams, today announced that it has acquired (subject to customary closing conditions) Reforge, an AI platform for product teams. The deal includes Reforge's team, learning platform, and AI-powered product development tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324623461/en/ Organizations are grappling with how to leverage AI to its full potential. In many cases, the problem is not how to code faster, but deciding what to build. That's the bottleneck slowing companies down today. Miro and Reforge are both solving this challenge for customers – tackling the need to build both at speed and with clear strategic direction. Miro brings a collaborative AI workflows platform that brings teams and AI together to plan, co
Xsolla and Stevenage FC Launch Charity Campaign With SpecialEffect to Make Gaming Accessible for All24.3.2026 14:00:00 CET | Press release
Donation Of 50 Accessible Setups Reinforces Xsolla’s Commitment To Inclusive Gaming Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, has partnered with Stevenage FC to launch a charity campaign with SpecialEffect in the United Kingdom, a charity dedicated to helping everyone to have the ability to enjoy video games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324722671/en/ Graphic: Xsolla Through the Official Partnership of Stevenage FC, Xsolla is donating the kit for the April 6th match vs Blackpool. SpecialEffect will be the primary kit brand for the match and will receive a percentage of the jersey sales leading up to the match and throughout the rest of the season. Xsolla will match donations from jersey sales, with the goal of using the funds to provide up to 50 Accessible Setups to disabled gamers at the end of the 2025-2026 season, and to support programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom